Tafluprost
Zioptan (tafluprost) is a small molecule pharmaceutical. Tafluprost was first approved as Zioptan on 2012-02-10. It is used to treat open-angle glaucoma in the USA. The pharmaceutical is active against prostaglandin F2-alpha receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
eye diseases | D005128 |
Trade Name
FDA
EMA
Zioptan (generic drugs available since 2019-08-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tafluprost
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZIOPTAN | Thea Pharma | N-202514 RX | 2012-02-10 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
tafluprost | ANDA | 2022-12-21 |
tafluprost | ANDA | 2022-12-21 |
zioptan | New Drug Application | 2022-10-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vivax malaria | D016780 | EFO_0007445 | B51 | 4 | 3 | 3 | 1 | 2 | 13 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malaria | D008288 | EFO_0001068 | B54 | 2 | 3 | 1 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Falciparum malaria | D016778 | EFO_0007444 | B50 | — | 3 | — | — | — | 3 |
Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
Healthy volunteers/patients | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TAFLUPROST |
INN | tafluprost |
Description | Tafluprost is a prostaglandin Falpha that is prostaglandin F2alpha in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side-chain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It has a role as a prostaglandin receptor agonist. It is a prostaglandins Falpha, an organofluorine compound and an isopropyl ester. It is functionally related to a prostaglandin F2alpha. |
Classification | Small molecule |
Drug class | prostaglandins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1 |
Identifiers
PDB | — |
CAS-ID | 209860-87-7 |
RxCUI | 1244607 |
ChEMBL ID | CHEMBL1963683 |
ChEBI ID | 66899 |
PubChem CID | 9868491 |
DrugBank | DB08819 |
UNII ID | 1O6WQ6T7G3 (ChemIDplus, GSRS) |
Target
Agency Approved
PTGFR
PTGFR
Organism
Homo sapiens
Gene name
PTGFR
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin F2-alpha receptor
Protein synonyms
FP prostanoid receptor, PGF receptor, PGF2 alpha receptor, prostaglandin receptor (2-alpha), Prostanoid FP receptor
Uniprot ID
Mouse ortholog
Ptgfr (19220)
prostaglandin F2-alpha receptor (P43117)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zioptan - Akorn
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 647 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
36 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more